Purdue’s Medical Services department is committed to providing balanced and accurate scientific and clinical information on Purdue products to help you make informed healthcare decisions. As a company founded by physicians, Purdue values the opportunity to communicate with healthcare professionals about the clinical information related to our medications.


Compendia Review

Purdue’s Medical Services department proactively and regularly reviews various drug information compendia to ensure Purdue product monographs are accurate, complete, and up-to-date as these resources are often utilized by healthcare professionals and consumers to help inform treatment decisions.

Collaborative Compendia Review Project

A collaborative initiative, led by Purdue Pharma, involving medical information specialists from 11 pharmaceutical companies proactively reviewed 270 drug summaries for 54 prescription drug products within 5 commonly-used online drug information compendia for misinformation. An alarming number of errors were identified in these top online drug information compendia. This study highlights need for healthcare professionals and consumers to utilize more than one drug information resource, one of which may include a pharmaceutical company’s medical information department, to obtain accurate and balanced product-specific information to help support treatment decisions.1

Complete study results were published online in the Annals of Pharmacotherapy on February 25, 2016 and are available here. Purdue’s press release describing the study and results is also available here.

Purdue Compendia Review

Between 2011 and 2013, pharmacists from the Medical Services (medical information) department
systematically reviewed drug summaries for Purdue’s opioid analgesic products within 7 leading online
drug information compendia for misinformation. Content corrections for errors were then submitted to
compendia editors and retrospectively categorized and classified. At least two months following
submission, the same drug summaries were then reexamined to assess the degree of error resolution.2

A total of 859 errors were identified, with the greatest percentage in Safety and Patient Education
categories. Across the 7 compendia, the complete or partial resolution of errors was 34%; therefore,
nearly two-thirds of the identified errors remain. Given the misinformation identified in this study,
healthcare professionals and consumers seeking reliable, on-label drug product information should
consult multiple sources, including a product’s Full Prescribing Information as well as manufacturers’
medical information departments.2

Complete study results were published online in the Journal of Opioid Management in August 2016 and are
available here. Purdue’s press release describing the study and results is also available here.


  1. Randhawa AS, et al. A collaborative assessment among 11 pharmaceutical companies of misinformation in commonly used online drug information compendia. Ann Pharmacother. 2016;50(5):352-359. doi: 10.1177/1060028016635196.
  2. Talwar SR, Randhawa AS, Dankiewicz EH, et al. Caveat emptor: Erroneous safety information about opioids in online drug-information compendia. J Opioid Manag. 2016 Jul/Aug.



We’re setting a new standard at Purdue Pharma, by learning from the past while focusing on the future. Watch here to learn more.

Skip the Video